ArticleClinicoEconomics and outcomes research : CEOR2021

Cost-Utility Analysis of Dapagliflozin Compared to Sulfonylureas for Type 2 Diabetes as Second-Line Treatment in Indian Healthcare Payer's Perspective.

Bhavani Shankara Bagepally et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.